ZNTL · Categories · Form 4

ZNTL - SEC Form 4 insider transactions

Zentalis Pharmaceuticals Inc. (ZNTL) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ZNTL

• 13d
  Director Campbell Shannon was granted 114,200 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 119d
  Chief Medical Officer Bruns Ingmar sold $7,998 worth of shares (3,297 units at $2.43), decreasing direct ownership by 9% to 33,332 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 119d
  PAO and PFO Vultaggio Vincent sold $97,557 worth of shares (40,224 units at $2.43), decreasing direct ownership by 22% to 146,506 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 119d
  CEO & President Eastland Julia Marie sold $21,239 worth of shares (8,755 units at $2.43), decreasing direct ownership by 10% to 79,133 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 125d
  PAO and PFO Vultaggio Vincent sold $7,875 worth of shares (3,096 units at $2.54), decreasing direct ownership by 2% to 186,730 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  SEC Form 4 filed by PAO and PFO Vultaggio Vincent

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  SEC Form 4 filed by Chief Legal Officer Bucher James B

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  SEC Form 4 filed by Chief Medical Officer Bruns Ingmar

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  SEC Form 4 filed by CEO & President Eastland Julia Marie

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 176d
  Large owner Matrix Capital Management Company, Lp sold $9,975,000 worth of shares (7,500,000 units at $1.33) (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 251d
  SEC Form 4 filed by Chief Legal Officer Bucher James B

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 356d
  Director Walker Luke Nathaniel was granted 57,603 shares, increasing direct ownership by 66% to 144,284 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 356d
  Director Skvarka Jan was granted 57,603 shares, increasing direct ownership by 39% to 207,154 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 356d
  Director Johnson David Michael was granted 57,603 shares, increasing direct ownership by 30% to 250,421 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 356d
  Director Kariuki Enoch was granted 57,603 shares, increasing direct ownership by 72% to 137,365 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 356d
  Director Myers Scott Dunseth was granted 57,603 shares, increasing direct ownership by 20% to 338,795 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  Chief Scientific Officer Lackner Mark sold $24,591 worth of shares (14,368 units at $1.71) and was granted 335,907 shares, increasing direct ownership by 168% to 512,856 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  Chief Legal Officer Paul Andrea was granted 934,041 shares and sold $22,643 worth of shares (13,230 units at $1.71), increasing direct ownership by 614% to 1,070,784 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  Chief Medical Officer Bruns Ingmar was granted 16,629 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  CEO & President Eastland Julia Marie was granted 59,388 shares, increasing direct ownership by 208% to 87,888 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 522d
  Chief Scientific Officer Lackner Mark sold $13,762 worth of shares (4,411 units at $3.12), decreasing direct ownership by 2% to 191,317 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 553d
  SEC Form 4 filed by Chief Medical Officer Bruns Ingmar

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 553d
  SEC Form 4 filed by CEO & President Eastland Julia Marie

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 573d
  Director Myers Scott Dunseth was granted 260,192 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 613d
  Principal Accounting Officer Vultaggio Vincent sold $5,098 worth of shares (1,603 units at $3.18), decreasing direct ownership by 5% to 33,855 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 718d
  Director Skvarka Jan was granted 41,581 shares, increasing direct ownership by 87% to 89,551 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 718d
  Director Kariuki Enoch was granted 41,581 shares, increasing direct ownership by 109% to 79,762 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 718d
  Director Johnson David Michael was granted 48,429 shares, increasing direct ownership by 34% to 192,818 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 739d
  Gallagher Cam sold $114,972 worth of shares (9,597 units at $11.98), decreasing direct ownership by 1% to 633,680 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 741d
  Walker Luke Nathaniel was granted 72,481 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 761d
  Hausman Diana sold $42,353 worth of shares (3,356 units at $12.62), decreasing direct ownership by 0.89% to 373,876 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 848d
  Epperly Melissa B, sold $29,435 worth of shares (2,573 units at $11.44), decreasing direct ownership by 0.57% to 451,449 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 848d
  Gallagher Cam sold $13,419 worth of shares (1,173 units at $11.44), decreasing direct ownership by 0.18% to 643,277 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Hausman Diana was granted 337,500 shares, increasing direct ownership by 849% to 377,232 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Lackner Mark was granted 141,000 shares and sold $18,291 worth of shares (1,585 units at $11.54), increasing direct ownership by 248% to 195,728 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Paul Andrea was granted 112,500 shares and sold $38,197 worth of shares (3,310 units at $11.54), increasing direct ownership by 268% to 149,973 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Gallagher Cam was granted 192,500 shares and sold $133,310 worth of shares (11,552 units at $11.54), increasing direct ownership by 39% to 644,450 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Epperly Melissa B, was granted 75,000 shares and sold $100,040 worth of shares (8,669 units at $11.54), increasing direct ownership by 17% to 454,022 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 855d
  Blackwell Kimberly was granted 250,000 shares and covered exercise/tax liability with 20,655 shares, increasing direct ownership by 90% to 484,145 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 888d
  Lackner Mark was granted 40,000 shares, increasing direct ownership by 245% to 56,313 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 901d
  Bunker Kevin D. gifted 24,158 shares, decreasing direct ownership by 3% to 834,931 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 977d
  Brownstein Carrie sold $207,298 worth of shares (10,628 units at $19.50), decreasing direct ownership by 9% to 105,685 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 977d
  Bunker Kevin D. sold $118,355 worth of shares (6,068 units at $19.50), decreasing direct ownership by 0.70% to 859,089 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 977d
  Epperly Melissa B, sold $106,926 worth of shares (5,482 units at $19.50), decreasing direct ownership by 1% to 387,691 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1000d
  SEC Form 4: Skvarka Jan sold $125,238 worth of shares (5,000 units at $25.05), decreasing direct ownership by 9% to 47,970 units

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1085d
  SEC Form 4 filed by Matrix Capital Management Company, Lp

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1089d
  SEC Form 4 filed by Johnson David Michael

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1089d
  SEC Form 4 filed by Kariuki Enoch

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1089d
  SEC Form 4 filed by Skvarka Jan

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1105d
  SEC Form 4 filed by Gallagher Cam

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1105d
  SEC Form 4 filed by Bunker Kevin D.

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1126d
  SEC Form 4 filed by Hausman Diana

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1195d
  SEC Form 4: Roth Iris was granted 52,500 shares

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1211d
  SEC Form 4: Epperly Melissa B, sold $158,005 worth of shares (7,851 units at $20.13) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 392,048 units to satisfy tax liability

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1211d
  SEC Form 4: Gallagher Cam sold $237,760 worth of shares (11,833 units at $20.09) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 491,270 units to satisfy withholding tax

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1211d
  SEC Form 4: Bunker Kevin D. sold $207,629 worth of shares (10,307 units at $20.14) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 865,157 units (withholding obligation)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1219d
  SEC Form 4: Gallagher Cam sold $222,678 worth of shares (10,000 units at $22.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,103 units

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1224d
  SEC Form 4: Bunker Kevin D. gifted 30,000 shares and was granted 91,354 shares, increasing direct ownership by 8% to 875,464 units

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 1224d
  SEC Form 4: Gallagher Cam was granted 161,092 shares, increasing direct ownership by 46% to 513,103 units

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)

Other ZNTL categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends